Table 1.
Comparison of Caucasian Patients’ Demographics, Dose-Normalized Tacrolimus Trough Concentrations, Tacrolimus Trough Concentrations, and Total Daily Tacrolimus Dose by CYP3A5 and CYP3A4 Genotype Status in the First 6 Months Post transplant
| Group 1 (n=4, 0.29%) | Group 2 (n=133, 9.7%) | Group 3 (n=1048, 76.7%) | Group 4 (n=13, 0.95%) | Group 5 (n=161, 11.8%) | Group 6 (n=7, 0.51%) | |
|---|---|---|---|---|---|---|
| Genotype | CYP3A5*3/*3 and CYP3A4 *221*22 | CYP3A5*3/*3 and CYP3A4*1/*22 | CYP3A5*3/*3 and CYP3A4*1/*1 | CYP3A5*1/*3 and CYP3A4*1/*22 | CYP3A5*1/*3 and CYP3A4*1/*1 | CYP3A5*1/*1 and CYP3A4*1/*1 |
| Age, mean, SD (yrs) | 49.9, 13.6 | 51.9, 13.1 | 51.2, 12.8 | 47.4, 13.4 | 51.3, 14.0 | 58.7, 13.4 |
| BMI, mean, SD (kg/m2) | 27.8, 3.7 | 27.9, 5.1 | 28.3, 5.6 | 28.4, 4.8 | 27.8, 5.2 | 26.7, 5.6 |
| Weight, mean, SD (kg) | 84.2, 13.1 | 82.5, 17.9 | 83.9, 20.0 | 88.1, 19.0 | 83.8, 18.3 | 73.5, 20.8 |
| Living donor transplant (%) | 75 | 63.2 | 66.5 | 53.9 | 68.3 | 71.4 |
| Female (%) | 25 | 37.6 | 37.2 | 23.1 | 32.9 | 57.1 |
| Diabetes at time of transplant (%) | 25 | 33.1 | 39.7 | 46.2 | 36.6 | 42.9 |
| Simultaneous pancreas kidney transplant (%) | 0 | 6.0 | 9.0 | 7.7 | 8.1 | 0 |
| Dose-normalized tacrolimus trough, median, IQR (ng/ml/mg of total daily dose) | 3.05, 2.12–1.32 | 2.18, 1.50–3.33 | 1.60, 1.10–2.40 | 1.06, 0.65–1.50 | 0.80, 0.56–1.20 | 0.69, 0.52–1.15 |
| Tacrolimus trough, median, IQR (ng/ml) | 8.25, 6.45–10.50 | 8.70, 7.00–10.60 | 8.50, 6.80–10.5 | 8.00, 6.20–9.50 | 7.80, 5.90–9.70 | 5.70, 4.10–8.40 |
| Daily tacrolimus dose, median, IQR (mg) | 2.50, 2.00–3.00 | 4.00, 2.50–6.00 | 5.00, 4.00–8.00 | 7.00, 5.00–12.00 | 9.00, 6.00–13.00 | 8.00, 6.00–13.00 |
BMI = body mass index; IQR = interquartile range; SD = standard deviation.